Diligence memo · auto-generated · as of July 2, 2026
CytoDyn Inc.
CytoDyn Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
CytoDyn Inc. operates in Biotechnology, based in Vancouver.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
CytoDyn Inc. has raised $158M in disclosed capital across 21 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $33M on 2015-06-30.
Most recent recorded round closed around 2022-04-07.
Valuation (modeled)modeled
Provath models CytoDyn Inc. at approximately $405M (range $44M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.42× the median modeled value of Series B Biotechnology companies in 2022–2024 (197 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 4.2 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 11.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 95% of Biotechnology peers (4293 compared).
Modeled value ranks above 81% of those peers.
Closest niche peers: Mt McKinley Medical Holding Corp USA, YAP Therapeutics Inc, Pinteon Therapeutics, Inc., OncXerna Therapeutics, Ltd., EpiBiologics, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.